Comparison · NCT00955968-deaths
Continue HAART vs Stop HAART: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Continue HAART vs Stop HAART: deaths from any cause. Trial comparisons, record NCT00955968-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00955968-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.00242 | 0.000663 | 0.00877 | wilson | |
| Risk in group 2 | 0.00485 | 0.00189 | 0.0124 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00243 | -0.0102 | 0.00458 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.499 | 0.0916 | 2.72 | log | |
| Odds ratio, group 1 over group 2 | 0.498 | 0.0909 | 2.72 | log | |
| Number needed to treat, for one fewer death from any cause on Continue HAART than on Stop HAART | 412 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Continue HAART | Participants would continue receiving HAART after delivery or other pregnancy outcome.~Highly active antiretroviral therapy (HAART): A combination of three or more HIV medications belonging to two or more drug classes | 2 | 827 | EG000 |
| Group 2 | Stop HAART | Participants would stop receiving HAART after delivery or other pregnancy outcome and resume when protocol-specified criteria were met.~Highly active antiretroviral therapy (HAART): A combination of three or more HIV medications belonging to two or more drug classes | 4 | 825 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
- From study entry to off study date (an average of 125 weeks of follow-up).
Source ClinicalTrials.gov
Trial
- Title
- IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women
- NCT number
- NCT00955968
- Phases
- PHASE4
- Conditions
- HIV Infection
- Interventions
- Highly active antiretroviral therapy (HAART)
- Lead sponsor
- International Maternal Pediatric Adolescent AIDS Clinical Trials Group
- Results first posted
- 2018-02-19
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00955968?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00955968-deaths